Abstract:Importance Pancreatic ductal adenocarcinoma (PDAC) is a relatively uncommon cancer, with approximately 60 430 new diagnoses expected in 2021 in the US. The incidence of PDAC is increasing by 0.5% to 1.0% per year, and it is projected to become the second-leading cause of cancer-related mortality by 2030. Observations Effective screening is not available for PDAC, and most patients present with locally advanced (30%-35%) or metastatic (50%-55%) disease at diagnosis. A multidisciplinary management approach is recommended. Localized pancreas cancer includes resectable, borderline resectable (localized and involving major vascular structures), and locally advanced (unresectable) disease based on the degree of arterial and venous involvement by tumor, typically of the superior mesenteric vessels. For patients with resectable disease at presentation (10%-15%), surgery followed by adjuvant chemotherapy with FOLFIRINOX (fluorouracil, irinotecan, leucovorin, oxaliplatin) represents a standard therapeutic approach with an anticipated median overall survival of 54.4 months, compared with 35 months for single-agent gemcitabine (stratified hazard ratio for death, 0.64 [95% CI, 0.48-0.86]; P = .003). Neoadjuvant systemic therapy with or without radiation followed by evaluation for surgery is an accepted treatment approach for resectable and borderline resectable disease. For patients with locally advanced and unresectable disease due to extensive vascular involvement, systemic therapy followed by radiation is an option for definitive locoregional disease control. For patients with advanced (locally advanced and metastatic) PDAC, multiagent chemotherapy regimens, including FOLFIRINOX, gemcitabine/nab-paclitaxel, and nanoliposomal irinotecan/fluorouracil, all have a survival benefit of 2 to 6 months compared with a single-agent gemcitabine. For the 5% to 7% of patients with a BRCA pathogenic germline variant and metastatic PDAC, olaparib, a poly (adenosine diphosphate [ADB]-ribose) polymerase inhibitor, is a maintenance option that improves progression-free survival following initial platinum-based therapy. Conclusions and Relevance Approximately 60 000 new cases of PDAC are diagnosed per year, and approximately 50% of patients have advanced disease at diagnosis. The incidence of PDAC is increasing. Currently available cytotoxic therapies for advanced disease are modestly effective. For all patients, multidisciplinary management, comprehensive germline testing, and integrated supportive care are recommended.

Pancreatic cancer.

Clinical diagnosis and management of pancreatic cancer: Markers, molecular mechanisms, and treatment options

Pancreatic cancer: diagnosis and treatments

Pancreatic Cancer: A Review.

Early Diagnosis of Pancreatic Cancer: The Key for Survival

Pancreatic cancer - diagnosis, risk factors and treatment. Literature review

Pancreatic Cancer: Rapid Evidence Review

Diagnosis and treatment of pancreatoblastoma in China.

Current status of non-surgical treatment of locally advanced pancreatic cancer

Pancreatic Tumorigenesis: Precursors, Genetic Risk Factors and Screening

Metastatic Mixed Acinar‐neuroendocrine Carcinoma of the Pancreas Treated by a Multidisciplinary Team: A Case Report and Brief Review of the Literature

Biological Characteristics of Pancreatic Ductal Adenocarcinoma: Initiation to Malignancy, Intracellular to Extracellular.

Pancreatic Cancer from Molecular Pathways to Treatment Opinion

Pancreatic Cancer: Current Multimodality Treatment Options and the Future Impact of Molecular Biological Profiling

Surgery for Pancreatic Cancer: Recent Controversies and Current Practice

Pancreatic cancer, pancreatogenic diabetes, type 2 diabetes mellitus

Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors

Earlier Diagnosis of Pancreatic Cancer: Is It Possible?

Landmarks in pancreatic cancer studies

Current Status and Future Prospect of Surgical Treatment for Pancreatic Cancer

Pancreatic ductal adenocarcinoma: Risk factors, screening, and early detection